ID 3129 - Lignany

PL: Lignany
EN: Lignans
Pdf: various food(s)/food constituent(s) not supported by pertinent human data

1.6. Zmniejszenie dyskomfortu związanego z okresem menopauzy (ID 1933, 2095, 3129, 3636)

The claimed effects are “menopause”, “phytoestrogenic properties”, and “contributes to physical well-being”. The Panel assumes that the target population is post-menopausal women.
In the context of the proposed wordings and clarifications provided by Member States, the Panel assumes that the claimed effects refer to the reduction of menopausal discomfort, which can be assessed as changes in the severity of symptoms related to menopause using validated questionnaires.
The Panel considers that reduction of menopausal discomfort is a beneficial physiological effect.

2.6. Zmniejszenie dyskomfortu związanego z okresem menopauzy (ID 1933, 2095, 3129, 3636)

The references provided in relation to these claims were reviews, human, animal and in vitro studies which assessed the effects of food(s)/food constituent(s) other than those which are the subject of the claim and/or health outcomes (e.g. antioxidant activity, apoptosis in cancer cells, antimicrobial activity) unrelated to the claimed effect. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claims.
No human studies which investigated the effects of the food(s)/food constituent(s) on reduction of menopausal discomfort were provided in relation to any of the claims evaluated in this section.
One in vitro study which investigated the oestrogenic effect of the food, which is the subject of the claim, was provided. The Panel considers that evidence provided in in vitro studies is not sufficient to predict the occurrence of an effect of the consumption of the food(s)/food constituent(s) on reduction of menopausal discomfort in vivo in humans.
The Panel concludes that a cause and effect relationship has not been established between the consumption of the food(s)/food constituent(s) which are the subject of the claims evaluated in this section and reduction of menopausal discomfort.

Warunki i możliwe ograniczenia stosowania oświadczenia

2 mg/serving